The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment
Abstract
PURPOSE: To determine the predictive value of vascular endothelial growth factor (VEGF) for relapse-free survival (RFS) and overall survival (OS) in primary node-positive breast cancer (NPBC) after adjuvant endocrine treatment or adjuvant chemotherapy. MATERIALS AND METHODS: VEGF was quantitatively measured in tumor cytosols from 362 consecutive patients with primary NPBC using an enzyme immunoassay for human VEGF 165. Adjuvant treatment was given to all patients, either as endocrine therapy (n = 250) or chemotherapy (n = 112). The median follow-up time was 56 months. RESULTS: Univariate analysis showed VEGF to be a significant predictor of RFS (P = .0289) and OS (P = .0004) in the total patient population and in patients who received adjuvant endocrine treatment (RFS, P = .0238; OS, P = .0121). In the group of patients who received adjuvant chemotherapy, no significant difference was seen in RFS, but a difference was seen in OS (P = .0235). Patients with bone recurrences tended to have lower VEGF expression (median, 2.17 pg/μg DNA) than patients with visceral metastasis (4.41 pg/μg), brain metastasis (8.29 pg/μg), or soft tissue recurrences (3.16 pg/μg). Multivariate analysis showed nodal status (P = .0004), estrogen receptor (ER) status (P < .0001), and tumor size (P = .0085) to be independent predictors of RFS. VEGF was found to be an independent predictor of OS (P = .0170; relative risk [RR] = 1.82), as were ER (P < .0001; RR = 5.19) and nodal status (P = .0002; RR = 2.58). For patients receiving adjuvant endocrine treatment, multivariate analysis showed VEGF content to be an independent predictor of OS (P = .0420; RR = 1.90) but not of RFS. CONCLUSION: The results suggest that VEGF 165 content in tumor cytosols is a predictor of RFS and OS in primary NPBC. VEGF content might also predict outcome after adjuvant endocrine treatment, but further studies in a prospective setting with homologous treatments are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062
Horak, E. R., Klenk, N., Leek, R., LeJeune, S., Smith, K., Stuart, N., Harris, A. L., Greenall, M., & Stepniewska, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)93150-l · Cited by 800
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
Antonelli-Orlidge, A., Saunders, K. B., Smith, S. R., & D'Amore, P. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4544 · Cited by 757
Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.845 · Cited by 723
P53 expression in breast cancer
Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 601
Microvessel quantitation and prognosis in invasive breast carcinoma
Bosari, S., Lee, A. K. C., DeLellis, R. A., Wiley, B. D., Heatley, G. J., & Silverman, M. L. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90344-3 · Cited by 549
Unemori, E. N., Ferrara, N., Bauer, E. A., & Amento, E. P. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041530317 · Cited by 526
Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.139 · Cited by 494
Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., & Pozza, F. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.454 · Cited by 464
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Toi, M., Inada, K., Suzuki, H., & Tominaga, T. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666040 · Cited by 362
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
Toi, M., Tominaga, T., & Kashitani, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550305 · Cited by 315
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
Linderholm, B., Tavelin, B., Grankvist, K., & Henriksson, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3121 · Cited by 264
Self-citationFisher, B., Redmond, C., Brown, A., Wickerham, D. L., Wolmark, N., Allegra, J., Escher, G., Lippman, M., Savlov, E., & Wittliff, J. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.4.227 · Cited by 260
Gasparini, G., Pozza, F., & Harris, A. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.15.1206 · Cited by 238
p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients
Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Fronzo, G. D., & Veronesi, U. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.965 · Cited by 236
Yoshiji, H., Harris, S. R., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 206
Quantitative analysis of vascular endothelial growth factor in primary breast cancer
Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T., & Tominaga, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960315)77:6<1101::aid-cncr15>3.0.co;2-5 · Cited by 193
Inhibition of angiogenesis by antiestrogens.
Gagliardi, A., & Collins, D. C. (1993) · PubMed · Cited by 179
Fox, S. B., Leek, R. D., Smith, K., Hollyer, J., Greenall, M., & Harris, A. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666186 · Cited by 170
Terrier, P., Townsend, A. J., Coindre, J., Triche, T. J., & Cowan, K. H. (1990) · Europe PMC (PubMed Central) · Cited by 162
Angiogenesis as a Predictor of Long-term Survival for Patients With Node-Negative Breast Cancer
Heimann, R., Ferguson, D. J. P., Powers, C., Recant, W. M., Weichselbaum, R. R., & Hellmän, S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.23.1764 · Cited by 154
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
Kölch, W., Martiny‐Baron, G., Kieser, A., & Marm�, D. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666036 · Cited by 142
Fentiman, I. S., & Mansel, R. E. (1991) · The Lancet · doi:10.1016/0140-6736(91)92172-x · Cited by 136
Adjuvant systemic therapy for resectable breast cancer.
Bonadonna, G., & Valagussa, P. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.2.259 · Cited by 120
Scott, P., Smith, K. J., Poulsom, R., Benedetti, A. D., Bicknell, R., & Harris, A. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.356 · Cited by 117
(1993) · International Journal of Cancer · doi:10.1002/ijc.2910530330 · Cited by 11
Cited by
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Metadata
- Authors
- Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., & Henriksson, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-07
- Volume
- 18
- Issue
- 7
- Pages
- 1423-1431
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1925212740
- Cited by
- 254
- References
- 34
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.